InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2021-01-25 | Josh Gottheimer(D-NJ05) | house | Sale | $1,001 - $15,000 |
| 2020-10-16 | Josh Gottheimer(D-NJ05) | house | Purchase | $1,001 - $15,000 |
| 2020-09-15 | Josh Gottheimer(D-NJ05) | house | Sale | $1,001 - $15,000 |
| 2020-05-28 | Josh Gottheimer(D-NJ05) | house | Purchase | $1,001 - $15,000 |
| 2020-05-15 | Josh Gottheimer(D-NJ05) | house | Purchase | $1,001 - $15,000 |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net revenues | $1.36B+4.0% | $1.31B+12.0% | $1.17B+17.7% | $993.2M+14.1% | $870.5M |
| Cost of goods sold | $611.9M-0.9% | $617.5M+11.6% | $553.6M+13.5% | $487.7M+3.2% | $472.6M |
| Gross profit | $749.0M+8.3% | $691.5M+12.4% | $615.1M+21.7% | $505.5M+27.1% | $397.8M |
| Research and development | $62.7M+15.2% | $54.4M+8.6% | $50.1M+7.1% | $46.8M+42.4% | $32.9M |
| Selling, general and administrative | $436.8M+1.2% | $431.8M+14.6% | $376.7M+10.7% | $340.1M+23.6% | $275.2M |
| Amortization of acquired intangible assets | $48.3M+50.7% | $32.0M-1.9% | $32.6M-31.2% | $47.4M+44.4% | $32.8M |
| Remeasurement of contingent consideration | -$23.0M | $0 | $0 | — | — |
| Gains on divestiture and sale of assets | $0+100.0% | -$2.0M-423.6% | -$382K+96.0% | -$9.6M | — |
| Impairment of intangible assets | $2.4M-77.1% | $10.4M | $0 | $0 | — |
| Total operating expenses | $527.1M+0.1% | $526.7M+14.7% | $459.1M+8.1% | $424.8M+37.9% | $308.1M |
| Operating income | $221.8M+34.5% | $164.9M+5.7% | $156.0M+93.2% | $80.8M-10.0% | $89.7M |
| Interest and other expense, net | -$9.7M+25.1% | -$13.0M+11.0% | -$14.6M+14.5% | -$17.1M-1.7% | -$16.8M |
| Income before provision for income taxes | $212.1M+39.6% | $151.9M+7.4% | $141.4M+122.2% | $63.6M | — |
| Provision for income taxes | $44.4M+29.4% | $34.3M+31.9% | $26.0M+28.4% | $20.3M | — |
| Net income | $167.7M+42.6% | $117.6M+1.9% | $115.4M+166.1% | $43.4M-45.4% | $79.5M |
| Net income per share - basic (in dollars per share) | $3K+43.5% | $2K+2.2% | $2K+167.1% | $850-45.9% | $2K |
| Net income per share - diluted (in dollars per share) | $3K+44.5% | $2K+2.2% | $2K+166.7% | $840-45.8% | $2K |
| Basic (in shares) | $50.3M-0.7% | $50.7M-0.2% | $50.8M-0.5% | $51.0M+0.7% | $50.7M |
| Diluted (in shares) | $50.7M-1.3% | $51.4M-0.0% | $51.4M+0.1% | $51.4M+0.1% | $51.3M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
3 Cash-Producing Stocks We Keep Off Our Radar
Will VASCADE MVP XL’s Expanded FDA Labeling Shift Haemonetics’ (HAE) Electrophysiology Growth Narrative
New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures
Riverwater Sustainable Value Strategy Awaits Haemonetics Corporation’s (HAE) Market Validation